Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition |
On February 14, 2017, Ohr Pharmaceutical, Inc., a Delaware
corporation, issued a press release announcing, among other
things, its results for the first quarter ended December 31,
2016. This press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference.
The information set forth or incorporated by reference in this
Item2.02 of this Current Report on Form 8-K, including the
applicable portion of the press release attached as Exhibit 99.1
hereto, is being furnished to the Securities and Exchange
Commission, shall not be deemed to be filed for purposes of
Section18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to the liabilities thereof,
nor shall it be deemed to be incorporated by reference into any
filing under the Exchange Act or under the Securities Act of
1933, as amended, except to the extent specifically provided in
any such filing.
| Item8.01. | Other Events. |
On February 14, 2017, the Company issued a press release
announcing, among other things, a strategic business update. A
copy of the press release is attached to this Current Report on
Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d)
Exhibits:
| 99.1 | Press release, dated February 14, 2017. | |
About Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)
Ohr Pharmaceutical, Inc. is a pharmaceutical company focused on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company’s development pipeline consists of several programs and indications at various stages of development. Its product pipeline includes Squalamine Lactate Ophthalmic Solution 0.2% (Squalamine, also known as OHR-102), SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry- Age-Related Macular Degeneration (AMD) and Non-Ophthalmology Assets. OHR-102 is a therapeutic product that provides a non-invasive therapy to improve vision outcomes. The SKS sustained release technology is designed to develop drug formulations for ocular disease. In the Company’s animal model for dry-AMD, mice are immunized with a carboxyethylpyrrole, which is bound to mouse serum albumin. It also owns various other compounds in earlier stages of development, including the PTP1b inhibitor Trodusquemine and related analogs. Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) Recent Trading Information
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) closed its last trading session down -0.25 at 1.10 with 1,177,768 shares trading hands.
